[go: up one dir, main page]

AR123648A1 - Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos - Google Patents

Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos

Info

Publication number
AR123648A1
AR123648A1 ARP210102713A ARP210102713A AR123648A1 AR 123648 A1 AR123648 A1 AR 123648A1 AR P210102713 A ARP210102713 A AR P210102713A AR P210102713 A ARP210102713 A AR P210102713A AR 123648 A1 AR123648 A1 AR 123648A1
Authority
AR
Argentina
Prior art keywords
4alkyl
alkyl
halo
haloc1
haloalkyl
Prior art date
Application number
ARP210102713A
Other languages
English (en)
Inventor
Hang Chu
Hongyan Guo
Lan Jiang
Jiayao Li
David W Lin
Hyung Pyun
- Wu Qiaoyin Jung
Hong Yang
Adam D Zajdlik
Jennifer R Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR123648A1 publication Critical patent/AR123648A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos para uso en el tratamiento o prevención de infección con el virus de la inmunodeficiencia humana (VIH). Los compuestos tienen la siguiente fórmula (1), incluyendo sus estereoisómeros y sus sales farmacéuticamente aceptables. También se describen métodos asociados con la preparación y uso de los compuestos descriptos, así como composiciones farmacéuticas que comprenden dichos compuestos. Reivindicación 1: Un compuesto de la fórmula (1) o una sal aceptable farmacéuticamente de este, en donde R¹ es arilo C₆₋₁₀ o heteroarilo de 5 a 10 miembros, en donde el arilo C₆₋₁₀ o heteroarilo de 5 a 10 miembros se sustituye opcionalmente con uno a cuatro RA¹, en donde cada RA¹ es independientemente halo, alquilo C₁₋₆, haloalquilo C₁₋₄, ciano, -O-alquilo C₁₋₄, o alquilo C₁₋₄-O-alquilo C₁₋₄; R² es H, alquilo C₁₋₆, o haloalquilo C₁₋₄; R³ es halo o -OR³ᵃ, en donde R³ᵃ es H, -alquilo C₁₋₆, -haloalquilo C₁₋₄, o -cicloalquilo C₃₋₆; o R³ᵃ y uno cualquiera de R², R⁵ᵃ, y R⁶ᵃ junto con los carbonos a los que están unidos forman un anillo heterocíclico de 4 a 6 miembros que contiene uno o dos heteroátomos seleccionados independientemente de N, O, y S; R³ᵇ es H, -alquilo C₁₋₆, -haloalquilo C₁₋₄, o -alquileno C₁₋₄-O-alquilo C₁₋₄; R⁴ᵃ es -alquilo C₁₋₆ o -haloalquilo C₁₋₄; R⁴ᵇ es H, halo, -alquilo C₁₋₆, o -haloalquilo C₁₋₄; W¹ es un enlace o -CR⁵ᵃR⁵ᵇ-; R⁵ᵃ y R⁵ᵇ son independientemente H, alquilo C₁₋₆, haloalquilo C₁₋₄, o halo; o R⁵ᵃ y R³ᵃ junto con los carbonos a los que están unidos forman un anillo heterocíclico de 4 a 6 miembros que contiene uno o dos heteroátomos seleccionados independientemente de N, O, y S; y R⁵ᵇ es H, alquilo C₁₋₆, haloalquilo C₁₋₄, o halo; W² es -CR⁶ᵃR⁶ᵇ- o -CR⁷ᵃ=CR⁷ᵇ-; R⁶ᵃ y R⁶ᵇ son independientemente H, alquilo C₁₋₆, haloalquilo C₁₋₄, halo, hidroxilo, ciano, -O-alquilo C₁₋₄, o alquileno C₁₋₄-O-alquilo C₁₋₄; o R⁶ᵃ y R³ᵃ junto con los carbonos a los que están unidos forman un anillo heterocíclico de 4 a 6 miembros que contiene uno o dos heteroátomos seleccionados independientemente de N, O, y S; y R⁶ᵇ es H, alquilo C₁₋₆, haloalquilo C₁₋₄, halo, hidroxilo, ciano, -O-alquilo C₁₋₄, o -alquileno C₁₋₄-O-alquilo C₁₋₄; R⁷ᵃ y R⁷ᵇ son independientemente H, halo, haloalquilo C₁₋₄, o alquilo C₁₋₆; o R⁷ᵃ y R⁷ᵇ junto con los carbonos a los que están unidos forman un arilo C₅₋₁₀ sustituido opcionalmente con uno a cuatro RA², en donde cada RA² es independientemente halo, ciano, o alquilo C₁₋₄.
ARP210102713A 2020-09-30 2021-09-30 Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos AR123648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063085704P 2020-09-30 2020-09-30

Publications (1)

Publication Number Publication Date
AR123648A1 true AR123648A1 (es) 2022-12-28

Family

ID=78463926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102713A AR123648A1 (es) 2020-09-30 2021-09-30 Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos

Country Status (10)

Country Link
US (2) US12421235B2 (es)
EP (1) EP4222152B1 (es)
JP (2) JP7691494B2 (es)
KR (1) KR20230079137A (es)
CN (1) CN116390924B (es)
AR (1) AR123648A1 (es)
AU (2) AU2021351491C1 (es)
CA (1) CA3192145A1 (es)
TW (1) TW202222798A (es)
WO (1) WO2022072520A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202544011A (zh) 2019-03-22 2025-11-16 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ感染症を治療するための四環式化合物及びその使用
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080879A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN119438457B (zh) * 2024-12-18 2025-12-02 成都迈科康生物科技有限公司 一种测定脂质体佐剂中有关物质的方法及其应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
HRP20070078A2 (hr) 2004-07-27 2007-05-31 Gilead Sciences Fosfonatni analozi spojeva koji inhibiraju hiv
WO2006088173A1 (ja) * 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
BRPI0610030B8 (pt) 2005-04-28 2022-01-11 Glaxosmithkline Llc Composto, composição farmacêutica, e, uso de um composto
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
EP1910363A4 (en) 2005-08-04 2010-05-26 Glaxosmithkline Llc INHIBITORS OF HIV INTEGRASE
CA2625673A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. Hiv integrase inhibitors
WO2007049675A1 (ja) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
CA2665538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
JP5564435B2 (ja) 2008-01-08 2014-07-30 メルク・シャープ・アンド・ドーム・コーポレーション Ｎ−置換ヒドロキシピリミジノンカルボキサミドの製造方法
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2009228398B2 (en) 2008-03-24 2014-07-03 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
ES2408654T3 (es) 2008-07-02 2013-06-21 Avexa Limited Tiazopirimidinonas y uso de las mismas
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
CN105198804B (zh) 2008-07-25 2018-03-23 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
DK2320908T3 (en) 2008-07-25 2014-03-10 Viiv Healthcare Co DOLUTEGRAVIR prodrugs
EA201170537A1 (ru) 2008-10-06 2011-12-30 Мерк Шарп Энд Домэ Корп. Ингибиторы вич-интегразы
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
JP5086478B2 (ja) 2008-12-11 2012-11-28 塩野義製薬株式会社 カルバモイルピリドンｈｉｖインテグラーゼ阻害剤及びそれらの中間体の合成
US20120022045A1 (en) * 2009-01-28 2012-01-26 Shankar Venkatraman Bridged compounds as hiv integrase inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
PT2444400T (pt) 2009-06-15 2018-06-06 Shionogi & Co Derivado de carbamoilpiridona policíclico substituído
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
EP2470014A4 (en) 2009-08-26 2013-01-16 Merck Sharp & Dohme HIV integrase inhibitors
KR20120087916A (ko) 2009-10-13 2012-08-07 엘랑코 애니멀 헬쓰 아일랜드 리미티드 마크로시클릭 인테그라제 억제제
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
AU2011221037A1 (en) 2010-02-26 2012-09-06 Japan Tobacco Inc. 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of same as HIV integrase inhibitor
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
CA2802492C (en) 2010-07-02 2018-10-16 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
ES2634490T3 (es) 2010-07-02 2017-09-28 Gilead Sciences, Inc. Derivados de ácido napht-2-ylacetico para tratar el sida
PT3456721T (pt) 2010-08-05 2021-05-04 Shionogi & Co Método de produção de compostos possuindo atividade inibitória de integrase de vih
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012058173A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
AP2013007249A0 (en) 2011-04-21 2013-11-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
PH12014500842A1 (en) 2012-04-20 2014-06-09 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
EP2865014A4 (en) 2012-06-25 2015-07-29 Sunpower Corp REINFORCEMENT FOR NETWORK OF SOLAR MODULES
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
DE102012220513B4 (de) 2012-11-12 2023-02-16 Bayerische Motoren Werke Aktiengesellschaft Verfahren und Vorrichtung zur Herstellung eines Druckgussteils
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
PE20151499A1 (es) * 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
WO2014104279A1 (ja) 2012-12-27 2014-07-03 日本たばこ産業株式会社 置換されたスピロピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
ES2656696T3 (es) 2013-05-17 2018-02-28 Merck Sharp & Dohme Corp. Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (es) * 2013-07-12 2018-07-21
EP3252058B1 (en) * 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
NO2717902T3 (es) 2014-06-20 2018-06-23
EP3196201B1 (en) 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
BR112017003663A2 (pt) 2014-08-27 2017-11-28 Viiv Healthcare Uk No 5 Ltd composto, composição, e, método para tratamento de infecção por hiv.
EP3229804B1 (en) 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3285582B1 (en) 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
KR20190057158A (ko) * 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087256A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP4299133A3 (en) 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
JP2020500866A (ja) 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
EP3752144B1 (en) * 2018-02-15 2022-12-28 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
MA52367A (fr) 2018-04-27 2021-03-03 Merck Sharp & Dohme Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
AR115455A1 (es) 2018-05-31 2021-01-20 Shionogi & Co Derivado de piridotriazina policíclica
MA52802A (fr) 2018-05-31 2021-04-14 Shionogi & Co Dérivé de pyridone polycyclique
CN112204029B (zh) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
ES2989103T3 (es) 2018-06-05 2024-11-25 Merck Sharp & Dohme Llc Compuestos de heterociclo tricíclico útiles como inhibidores de la integrasa del VIH
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020004443A1 (ja) 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
AU2019359539A1 (en) 2018-10-10 2021-04-29 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
EA202190974A1 (ru) 2018-10-22 2022-02-02 Борд Оф Риджентс Оф Зэ Юниверсити Оф Небраска Противовирусные пролекарства и их наносоставы
CN120535538A (zh) 2018-11-29 2025-08-26 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
TW202544011A (zh) 2019-03-22 2025-11-16 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
CN113795491B (zh) * 2019-04-30 2024-09-03 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN113226327B (zh) 2019-07-11 2022-05-17 南京征祥医药有限公司 可用于治疗流感病毒感染的化合物
WO2021093846A1 (zh) 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 新型四环杂环化合物及其药物用途
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
JP7776335B2 (ja) 2019-11-28 2025-11-26 塩野義製薬株式会社 多環性ピリドピラジン誘導体
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ感染症を治療するための四環式化合物及びその使用
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
TW202227445A (zh) 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
ES3048138T3 (en) 2021-02-16 2025-12-09 Merck Sharp & Dohme Llc Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Also Published As

Publication number Publication date
TW202222798A (zh) 2022-06-16
CA3192145A1 (en) 2022-04-07
AU2021351491A1 (en) 2023-05-04
WO2022072520A1 (en) 2022-04-07
JP2024164234A (ja) 2024-11-26
EP4222152B1 (en) 2025-12-31
US12421235B2 (en) 2025-09-23
AU2021351491C1 (en) 2025-06-12
JP7691494B2 (ja) 2025-06-11
CN116390924B (zh) 2025-11-07
KR20230079137A (ko) 2023-06-05
CN116390924A (zh) 2023-07-04
JP2023543059A (ja) 2023-10-12
US20220135565A1 (en) 2022-05-05
AU2024267005A1 (en) 2024-12-19
AU2021351491B2 (en) 2024-09-05
EP4222152A1 (en) 2023-08-09
US20240246975A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
AR123648A1 (es) Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos
AR117616A1 (es) Compuestos anti-vih
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR100645A1 (es) Derivados de pirazolo-pirimidina
PE20191260A1 (es) Compuestos inhibidores del vih
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
PE20190968A1 (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
PE20201414A1 (es) Derivado policiclico de piridona
AR118050A1 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
PE20081113A1 (es) Inhibidores virales policiclicos
AR098723A1 (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
AR114564A1 (es) DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco
AR112794A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh
AR126048A1 (es) Derivados heterocíclicos condensados